Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art.
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state-of-the-art.
Journal: Expert review of anticancer therapy
Published: May 15, 2026
Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium.
Journal: Current oncology (Toronto, Ont.)
Published: March 31, 2025
Clinical Trials-Real-World Data to Build a Future for Our Patients.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 10, 2024
Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
Journal: Journal for immunotherapy of cancer
Published: October 17, 2023
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
Journal: International journal of molecular sciences
Published: October 07, 2023
Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: May 19, 2023
Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity.
Journal: Expert review of anticancer therapy
Published: May 17, 2023
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
Journal: BMC cancer
Published: September 09, 2022
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.
Journal: Cold Spring Harbor perspectives in medicine
Published: February 05, 2017
Last Updated: 09/26/2026